- Records
- 19
- Recruiting
- 11
- Recruiting sites
- 613
- Countries
- 18
ClinicalTrials.gov registry snapshot / 2026-07-24Peptide trials,
Peptide trials,
without the maze.
Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.
268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program
Study status is not drug rank.
Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.
- Records
- 52
- Recruiting
- 10
- Recruiting sites
- 170
- Countries
- 7
- Records
- 37
- Recruiting
- 10
- Recruiting sites
- 73
- Countries
- 3
- Records
- 24
- Recruiting
- 10
- Recruiting sites
- 935
- Countries
- 28
- Records
- 27
- Recruiting
- 6
- Recruiting sites
- 1,581
- Countries
- 36
- Records
- 30
- Recruiting
- 5
- Recruiting sites
- 155
- Countries
- 6
- Records
- 8
- Recruiting
- 4
- Recruiting sites
- 339
- Countries
- 23
- Records
- 31
- Recruiting
- 3
- Recruiting sites
- 774
- Countries
- 34
- Records
- 15
- Recruiting
- 3
- Recruiting sites
- 3
- Countries
- 1
- Records
- 34
- Recruiting
- 2
- Recruiting sites
- 450
- Countries
- 27
- Records
- 9
- Recruiting
- 2
- Recruiting sites
- 4
- Countries
- 3
- Records
- 9
- Recruiting
- 1
- Recruiting sites
- 8
- Countries
- 1
- Records
- 5
- Recruiting
- 0
- Recruiting sites
- 0
- Countries
- 0
Official registry finder
Filter the exact records.
Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.
31matching registry records
Matching recruiting site observations289
| Program and record | Status | Phase and enrollment | Locations | Primary completion | Registry update | Source |
|---|---|---|---|---|---|---|
| A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001 / HF-POLARIS / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 35,610 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 23, 2029estimated | Jul 15, 2026ClinicalTrials.gov | Open NCT07567001 ↗ |
| AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571005 / AMAZE 3 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3300 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 12, 2028estimated | Jul 13, 2026ClinicalTrials.gov | Open NCT07571005 ↗ |
| AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571109 / AMAZE 4 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3300 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 26, 2028estimated | Jul 13, 2026ClinicalTrials.gov | Open NCT07571109 ↗ |
| A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3460 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 20, 2030estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07253285 ↗ |
| A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or ObesityNCT07243171 / Hangzhou Sciwind Biosciences Co., Ltd. | RecruitingVerified 2025-10 | Phase 1 / Phase 284 estimated | 1 matching recruitingBeijing, Beijing Municipality, 100029, China | Aug 3, 2026estimated | Jan 28, 2026ClinicalTrials.gov | Open NCT07243171 ↗ |
| A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure TherapyNCT07387094 / Hangzhou Sciwind Biosciences Co., Ltd. | RecruitingVerified 2026-01 | Phase 3140 estimated | 1 matching recruitingBeijing, Beijing Municipality, China | Dec 16, 2027estimated | Apr 14, 2026ClinicalTrials.gov | Open NCT07387094 ↗ |
| A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure TherapyNCT07434050 / Hangzhou Sciwind Biosciences Co., Ltd. | RecruitingVerified 2026-01 | Phase 3140 estimated | 1 matching recruitingShanghai, Shanghai Municipality, 200025, China | Jun 19, 2028estimated | Apr 13, 2026ClinicalTrials.gov | Open NCT07434050 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesNCT07282600 / ENLIGHTEN-2 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 31,035 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07282600 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesNCT07321886 / ENLIGHTEN-1 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 31,980 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07321886 ↗ |
| Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightNCT07353931 / ENLIGHTEN-4 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 3900 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07353931 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT07369011 / ENLIGHTEN-3 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 3800 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07369011 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinNCT07392190 / ENLIGHTEN-6 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 3900 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07392190 ↗ |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07351045 / Enith1 / Hoffmann-La Roche | RecruitingVerified 2026-07 | Phase 32,000 estimated | 14 matching recruitingZhenjiang, Jiangsu, 212002, China / Xianyang, Shaanxi, 712000, China / Jinan, Shandong, 250013, China / 11 more areas | Jul 24, 2028estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT07351045 ↗ |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesNCT07351058 / Enith2 / Hoffmann-La Roche | RecruitingVerified 2026-07 | Phase 31,600 estimated | 20 matching recruitingKaifeng, Henan, 475001, China / Xuzhou, Jiangsu, 221002, China / Zhenjiang, Jiangsu, 212002, China / 17 more areas | Aug 7, 2028estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT07351058 ↗ |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese ParticipantsNCT07626515 / Hoffmann-La Roche | RecruitingVerified 2026-07 | Phase 136 estimated | 1 matching recruitingBeijing, 100034, China | Apr 30, 2027estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07626515 ↗ |
| A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 DiabetesNCT07670416 / Hoffmann-La Roche | RecruitingVerified 2026-07 | Phase 3300 estimated | 12 matching recruitingXianyang, Shaanxi, 712000, China / Ningbo, Zhejiang, 315010, China / Beijing, 100044, China / 9 more areas | Feb 24, 2028estimated | Jul 14, 2026ClinicalTrials.gov | Open NCT07670416 ↗ |
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 / MARITIME-CV / Amgen | RecruitingVerified 2026-07 | Phase 312,800 estimated | 40 matching recruitingBengbu, Anhui, 233300, China / Beijing, Beijing Municipality, 100020, China / Beijing, Beijing Municipality, 100050, China / 37 more areas | Jun 30, 2028estimated | Jul 24, 2026ClinicalTrials.gov | Open NCT07037433 ↗ |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 / MARITIME-HF / Amgen | RecruitingVerified 2026-06 | Phase 35,056 estimated | 50 matching recruitingHefei, Anhui, 230601, China / Beijing, Beijing Municipality, 100020, China / Beijing, Beijing Municipality, 100037, China / 46 more areas | Jun 30, 2028estimated | Jul 2, 2026ClinicalTrials.gov | Open NCT07037459 ↗ |
| Efficacy of Mazdutide for Treating PCOSNCT06519656 / Shanghai Zhongshan Hospital | RecruitingVerified 2024-10 | Phase 1 / Phase 250 estimated | 1 matching recruitingShanghai, 200032, China | Dec 31, 2025estimated | Oct 24, 2024ClinicalTrials.gov | Open NCT06519656 ↗ |
| A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityNCT06862908 / Innovent Biologics (Suzhou) Co. Ltd. | RecruitingVerified 2025-07 | Phase 2141 estimated | 1 matching recruitingBeijing, Beijing Municipality, 100037, China | Sep 24, 2026estimated | Jul 11, 2025ClinicalTrials.gov | Open NCT06862908 ↗ |
| A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2NCT06931028 / Innovent Biologics (Suzhou) Co. Ltd. | RecruitingVerified 2025-06 | Phase 3260 estimated | 1 matching recruitingBeijing, 100191, China | May 7, 2027estimated | Jun 29, 2025ClinicalTrials.gov | Open NCT06931028 ↗ |
| A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)NCT06937749 / Innovent Biologics (Suzhou) Co. Ltd. | RecruitingVerified 2025-11 | Phase 2165 estimated | 1 matching recruitingBeijing, Beijing Municipality, 100044, China | Apr 30, 2026estimated | Nov 20, 2025ClinicalTrials.gov | Open NCT06937749 ↗ |
| GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)NCT07083154 / The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | RecruitingVerified 2026-03 | Phase 3420 estimated | 6 matching recruitingChangzhou, Jiangsu, China / Nanjing, Jiangsu, 210000, China / Nanjing, Jiangsu, 210008, China / 3 more areas | Aug 1, 2029estimated | Mar 5, 2026ClinicalTrials.gov | Open NCT07083154 ↗ |
| A Study of IBI362 in Chinese Adolescents With Obesity or OverweightNCT07255209 / Innovent Biologics (Suzhou) Co. Ltd. | RecruitingVerified 2026-01 | Phase 3180 estimated | 1 matching recruitingHangzhou, Zhejiang, 310052, China | Oct 31, 2027estimated | Jan 8, 2026ClinicalTrials.gov | Open NCT07255209 ↗ |
| Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/ObesityNCT07469800 / Innovent Biologics (Suzhou) Co. Ltd. | RecruitingVerified 2026-05 | Phase 3336 estimated | 1 matching recruitingShanghai, Shanghai Municipality, China | Aug 1, 2026estimated | May 27, 2026ClinicalTrials.gov | Open NCT07469800 ↗ |
| ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight ManagementNCT07517042 / Shanghai Zhongshan Hospital | RecruitingVerified 2025-12 | Not applicable420 estimated | 13 matching recruitingChongqing, Chongqing Municipality, 400000, China / Fuzhou, Fujian, 350000, China / Xiamen, Fujian, 361003, China / 8 more areas | Dec 2028estimated | Apr 8, 2026ClinicalTrials.gov | Open NCT07517042 ↗ |
| GLP-1 Therapy After Bariatric Surgery in Chinese Patients With ObesityNCT07633639 / China-Japan Friendship Hospital | RecruitingVerified 2026-05 | Not applicable200 estimated | 1 matching recruitingBeijing, China | May 1, 2028estimated | Jun 8, 2026ClinicalTrials.gov | Open NCT07633639 ↗ |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 34,500 estimated | 39 matching recruitingBeijing, 100015, China / Beijing, 100034, China / Beijing, 100050, China / 36 more areas | Aug 2030estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07165028 ↗ |
| Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are OverweightNCT07467447 / GZBF / Hudson Biotech | RecruitingVerified 2026-03 | Phase 2300 estimated | 1 matching recruitingShenzhen, Guangdong, 518036, China | Mar 14, 2027estimated | Mar 12, 2026ClinicalTrials.gov | Open NCT07467447 ↗ |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisNCT06632444 / Boehringer Ingelheim | RecruitingVerified 2026-07 | Phase 31,800 estimated | 49 matching recruitingBeijing, 100015, China / Beijing, 100044, China / Beijing, 100050, China / 44 more areas | Dec 27, 2031estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT06632444 ↗ |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisNCT06632457 / Boehringer Ingelheim | RecruitingVerified 2026-07 | Phase 31,590 estimated | 34 matching recruitingBeijing, 100015, China / Beijing, 100044, China / Beijing, 100050, China / 30 more areas | Jun 5, 2029estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT06632457 ↗ |
Recruiting location footprint
Country and US state routes.
Counts are site observations across registry records, not unique facilities. The same research center can appear in multiple studies. Open the exact NCT record before treating a location as current.
Clinical trial finder FAQ
Status, location, and enrollment are different fields.
These answers prevent the most common registry-search errors before a reader follows an official source.
Are any Retatrutide clinical trials recruiting?
Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.
How do I find a peptide clinical trial near me?
Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.
Does Recruiting mean I can join the trial?
No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.
Are the drugs in this clinical trial finder FDA approved?
A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.
Why do only some registry records show posted results?
11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.
How current is the peptide clinical trial data?
The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.
Evidence boundary
A registry finder, not an enrollment service.
A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.
Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.
Read the official API documentation ↗Understand evidence categories →